India - English - Central Drugs Standard Control Organization

ch.bhagat - daunorubicin hcl. - inj - 20mg - vial

India - English - Central Drugs Standard Control Organization

cipla - daunorubicin - inj - 20mg - 10ml

India - English - Central Drugs Standard Control Organization

cadila ph. - daunorubicin - vial - 20mg(+mannitol 200mg) - 1

Israel - English - Ministry of Health

novartis israel ltd - ondansetron as hydrochloride dihydrate - solution for injection - ondansetron as hydrochloride dihydrate 2 mg/ml - ondansetron - ondansetron - adults:zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:zofran is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ≥6 months, and for the prevention and treatment of ponv in children aged ≥ 1 month.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd - midostaurin - leukemia, myeloid, acute; mastocytosis - antineoplastic agents - rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (aml) who are flt3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated haematological neoplasm (sm ahn), or mast cell leukaemia (mcl).

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - gemtuzumab ozogamicin - leukemia, myeloid, acute - antineoplastic agents - mylotarg is indicated for combination therapy with daunorubicin (dnr) and cytarabine (arac) for the treatment of patients age 15 years and above with previously untreated, de novo cd33-positive acute myeloid leukaemia (aml), except acute promyelocytic leukaemia (apl).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - tretinoin, quantity: 10 mg - capsule, soft - excipient ingredients: purified water; glycerol; yellow beeswax; iron oxide yellow; gelatin; titanium dioxide; iron oxide red; soya oil; partially hydrogenated soya oil; hydrogenated soya oil; maize starch; sorbitol; mannitol - vesanoid should be used for induction of remission in acute promyelocytic leukemia (apl; fab classification aml-m3). previously untreated patients as well as patients who relapse after or are refractory to standard chemotherapy (daunorubicin and cytosine arabinoside (ara-c)or equivalent therapies) may be treated with vesanoid. following complete remission, consolidation full dose chemotherapy should be employed. a loss of responsiveness to vesanoid has been reported among patients maintained on vesanoid. the median time to relapse for patients maintained on vesanoid is 4 to 6 months.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - isavuconazonium sulfate, quantity: 186.3 mg (equivalent: isavuconazole, qty 100 mg) - capsule - excipient ingredients: potassium acetate; gellan gum; iron oxide red; sodium lauryl sulfate; titanium dioxide; hypromellose; disodium edetate; magnesium citrate; microcrystalline cellulose; purified talc; colloidal anhydrous silica; stearic acid; propylene glycol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; ethanol absolute; iron oxide black; potassium hydroxide - cresemba is indicated in adults for the treatment of ? invasive aspergillosis ? mucormycosis in patients for whom amphotericin b is inappropriate (see section 4.4 special warnings and precautions for use and section 5.1 pharmacodynamic properties),consideration should be given to official guidance on the appropriate use of antifungal agents.

Namibia - English - Namibia Medicines Regulatory Council

pfizer laboratories (pty) ltd - daunorubicin hydrochloride - injectable solution - 20mg

Malta - English - Medicines Authority

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - powder and solvent for solution for injection - daunorubicin 20 mg - antineoplastic agents